SCHEMBL24670563

SCHEMBL24670563

CCCN1CC(CO)(CO)C1

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
GBA1 P04062 1/20 0.35
L3MBTL3 Q96JM7 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10646186 0.79 KDM4E (0.33) KDM4E
SCHEMBL25922429 0.79 DRD2 (0.30)
SCHEMBL27798489 0.78 GLB1 (0.39) GBA1
SCHEMBL26381410 0.77
SCHEMBL9851577 0.76 KDM4E (0.40) KDM4E
SCHEMBL24108242 0.73
SCHEMBL10639698 0.73
SCHEMBL4550233 0.72
SCHEMBL26381296 0.71
SCHEMBL18976756 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340599-A1 AMPK ACTIVATORS KALLYOPE, INC. 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340599-A1 AMPK ACTIVATORS PRKAG1, PRKAG2, PRKAA1 KDM4E 636/4885GBA1 2994/4885L3MBTL3 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.